Table 3. Summary of GRADE Recommendations for
Therapies by Domain (cont'd)
Indication
Recommended
Strong
Recommended
Conditional
Not
recommended
Strong
No recs due
to lack of
evidence
Psoriasis
[plaque]
Topical
therapies,
phototherapy,
DMARDs
(MTX, LEF,
CyA), TNFi,
IL12/23i,
IL17i, PDE4i
Nail psoriasis TNFi,
IL12/23i
Topical therapies,
procedural therapies,
DMARDs (CyA,
LEF, Acitretin,
MTX), IL17i,
PDE4i
Grey, italicized text identifies conditional recommendations where recommendations are
based on abstract data only.
Grey, italicized text in [brackets] identifies a conditional recommendation based only on
abstract data from a small open-label proof-of-concept trial.
Table 4. Biologic and Other New Agents
Target/Agent IL-17 IL-12/23 PDE-4 TNF-α
Adalimumab (Humira) ✔
Certolizumab (Cimzia) ✔
Etanercept (Enbrel) ✔
Infliximab (Remicade) ✔
Golimumab (Simponi) ✔
Ustekinumab (Stelara) ✔
Apremilast (Otezla) ✔
Secukinumab (Cosentyx) ✔
Ixekizumab ✔
7
